NWBO: Once In A Decade Best Stock Investment -- Regulatory Approvals Coming! [Dec10, 2022 在第一页加了中文简述]

Market rebounded from a loss of 500 points to a rise of 500 point, an unbelievable swing of 1000 point in less than one hour! The reason may be short squeeze and/or manipulation, most likely a combination of the two.

Waiting for the days for a huge short squeeze re NWBO.

1665676680092.png
 
Pressures are building from patients advocacy groups on regulatory agencies (Health Canada, US FDA, etc) to approve DCVax-L as treatments for both nGBM and rGBM patients worldwide. One heart wrenching but yet encouraging story is that of Ted's. Ted was diagnosed with GBM years ago. He is a hero and truly a great inspiration.



starting from
29:14 this ever-changing disease as I've said I am currently researching DC vaxel and I feel it may be the most exciting possibility for GBM that I have ever seen this is the largest increase in overall survival in both new and recurrent GBM cases and we are not talking about weeks of additional time as has happened with the Optum and temozolomide in the past instead some of the initial results are reported as multiples of the current median survival times I must say all of this with caution as we need to await the study to be both peer-reviewed and approved by the FDA and other medical bodies around the globe continuing on discussion about DC vaxel how does the process work it uses dendritic cells those dendritic cells are the quarterbacks of your immune system and they harness them if I explain the process the best way to do it in a nutshell is you go through a process called leukoprisis it's a two to three hour process where they extract blood and put it into a centrifuge to extract the dendritic cells next they must have a representative tumor sample from the most recent tumor that was Flash Frozen without any preservatives or saline and it needs to be stored at minus 70 degrees Fahrenheit they will need two to three grams of the tumor tissue this tumor is broken down into its constituent Parts using enzymes becoming a togulous tumorizate these parts are then exposed to the dendritic cells the dendritic cells develop antibodies to the cancer these dendritic cells have learned how to recognize your specific cancer next they concentrate the dendritic cells and produce vials which are stored in liquid nitrogen finally this new vaccine is given to the patient in specific doses over a prescribed timeline the vaccine of learned dendritic cells are injected into your arm muscle where they make their way to the lymphatic system once there they interact with T cells who then multiply and rally the entire immune system to Target the cancer now that the immune system can see the cancer it goes about killing it success has been strong and there have been almost zero side effects which is extremely rare as we know with a lot of Cancer Care if there is a recurrence down the road they can repeat the process to Target the new version of the glioblastoma I am currently working to bring DC vaxel into Canada and to try to have it approved by Health Canada additionally I am working to have it approved by the cancer agency and add it to the standard of care for all GBM patients it should be noted that the researchers believe this same treatment may be successful with all solid forms of cancer this is truly amazing you will notice the picture on the side it says pftm that stands for our slogan

Ed at 32:43
 
Part of Northwest Bio's patent portfolio:

Patents Assigned to Northwest Biotherapeutics, Inc. [based on Northwest Biotherapeutics, Inc. Patent Filings]

  • OPTIMALLY ACTIVATED DENDRITIC CELLS THAT INDUCE AN IMPROVED OR INCREASED ANTI-TUMOR IMMUNE RESPONSE


    Publication number: 20220145246

    Abstract: The present disclosure provides populations of cells comprising partially mature and optimally activated dendritic cells that can be used for administration to individuals having a cancer and/or tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 10 to about 19 hours, upon administration efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual. Once in a lymph node the now fully mature antigen presenting dendritic cells secrete the appropriate cytokines (e.g., TNF?, IL-6, IL-8, and/or IL-12) and contact T cells inducing a substantial and optimal clinical and/or anti-tumor immune response.

    Type: Application

    Filed: September 17, 2021

    Publication date: May 12, 2022

    Applicant: Northwest Biotherapeutics, Inc.

    Inventor: Marnix Leo Bosch
  • Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response


    Patent number: 11124768

    Abstract: The present disclosure provides populations of cells comprising partially mature and optimally activated dendritic cells that can be used for administration to individuals having a cancer and/or tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 10 to about 19 hours, upon administration efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual. Once in a lymph node the now fully mature antigen presenting dendritic cells secrete the appropriate cytokines (e.g., TNFa, IL-6, IL-8, and/or IL-12) and contact T cells inducing a substantial and optimal clinical and/or anti-tumor immune response.

    Type: Grant

    Filed: June 29, 2016

    Date of Patent: September 21, 2021

    Assignee: Northwest Biotherapeutics, Inc.

    Inventor: Marnix Leo Bosch
  • GENERATION OF DENDRITIC CELLS FROM MONOCYTIC DENDRITIC PRECURSOR CELLS WITH GM-CSF IN THE ABSENCE OF ADDITIONAL CYTOKINES


    Publication number: 20210102169

    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14? and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN?, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.

    Type: Application

    Filed: August 3, 2020

    Publication date: April 8, 2021

    Applicant: Northwest Biotherapeutics, Inc.

    Inventors: Benjamin A. Tjoa, Marnix L. Bosch
  • Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines


    Patent number: 10731130

    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14 and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN?, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.

    Type: Grant

    Filed: July 30, 2015

    Date of Patent: August 4, 2020

    Assignee: NORTHWEST BIOTHERAPEUTICS, INC.

    Inventors: Benjamin A. Tjoa, Marnix L. Bosch
  • METHODS RELATING TO ACTIVATED DENDRITIC CELL COMPOSITIONS AND IMMUNOTHERAPEUTIC TREATMENTS FOR SUBJECTS WITH ADVANCED CANCERS


    Publication number: 20190046568

    Abstract: The present disclosure provides partially mature and activated dendritic cells that produce levels of cytokines/chemokines, for example, one or any combination of and/or all of IL-6, IL-8, IL-12 and/or TNF?, that are correlated with improved clinical outcomes, significantly increased survival times and significantly increased times to tumor or cancer recurrence. The determined threshold amounts of these cytokines can be used for (i) a immunotherapeutic potency test for activated dendritic cells, (ii) selecting responder patients, (iii) rejecting non-responder patients, and (iv) to screen for dendritic cell activation or maturation agents that can also induce the production of the threshold amount of the cytokines/chemokines.

    Type: Application

    Filed: September 14, 2016

    Publication date: February 14, 2019

    Applicant: Northwest Biotherapeutics, Inc.

    Inventor: Marnix L. BOSCH
  • OPTIMALLY ACTIVATED DENDRITIC CELLS THAT INDUCE AN IMPROVED OR INCREASED ANTI-TUMOR IMMUNE RESPONSE


    Publication number: 20180187145

    Abstract: The present disclosure provides populations of cells comprising partially mature and optimally activated dendritic cells that can be used for administration to individuals having a cancer and/or tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 10 to about 19 hours, upon administration efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual. Once in a lymph node the now fully mature antigen presenting dendritic cells secrete the appropriate cytokines (e.g., TNF?, IL-6, IL-8, and/or IL-12) and contact T cells inducing a substantial and optimal clinical and/or anti-tumor immune response.

    Type: Application

    Filed: June 29, 2016

    Publication date: July 5, 2018

    Applicant: Northwest Biotherapeutics, Inc.

    Inventor: Marnix Leo Bosch
  • QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS


    Publication number: 20170363625

    Abstract: The present invention provides methods for evaluating the quality of a preparation of antigen presenting cells, such as dendritic cells. Assays for antigen-independent co-stimulation of T cells and for presentation of predetermined antigen by APCs are provided.

    Type: Application

    Filed: May 31, 2017

    Publication date: December 21, 2017

    Applicant: Northwest Biotherapeutics, Inc.

    Inventors: Gopi Shankar, Patricia Anne Lodge, Alan Norman Brunelle
  • Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis


    Patent number: 9566294

    Abstract: The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicants' surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.

    Type: Grant

    Filed: April 2, 2013

    Date of Patent: February 14, 2017

    Assignee: Northwest Biotherapeutics, Inc.

    Inventors: Gerald P. Murphy, Alton L. Boynton, Anil Sehgal
  • Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines


    Patent number: 9102917

    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14? and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN?, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.

    Type: Grant

    Filed: March 5, 2013

    Date of Patent: August 11, 2015

    Assignee: Northwest Biotherapeutics, Inc.

    Inventors: Benjamin A. Tjoa, Marnix L. Bosch
  • THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS


    Publication number: 20140072564

    Abstract: The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicants' surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.

    Type: Application

    Filed: April 2, 2013

    Publication date: March 13, 2014

    Applicant: NORTHWEST BIOTHERAPEUTICS, INC.

    Inventor: Bridget Murphy
  • Generation of Dendritic Cells from Monocytic Dendritic Precursor Cells with GM-CSF in the Absence of Additional Cytokines


    Publication number: 20130273654

    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14? and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN?, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.

    Type: Application

    Filed: March 5, 2013

    Publication date: October 17, 2013

    Applicant: Northwest Biotherapeutics, Inc.

    Inventors: Benjamin A. Tjoa, Marnix L. Bosch
  • Tangential flow filtration devices and methods for leukocyte enrichment


    Patent number: 8518636

    Abstract: The present invention provides tangential flow filtration devices and methods for enriching a heterogenous mixture of blood constituents for leukocytes by removal of non-leukocyte blood constituents. In one particular embodiment the device can provide a composition enriched in monocytes.

    Type: Grant

    Filed: April 13, 2010

    Date of Patent: August 27, 2013

    Assignee: Northwest Biotherapeutics, Inc.

    Inventors: Marnix L. Bosch, Paul C. Harris, Steven J. Monahan, Allen Turner, Alton L. Boynton, Patricia A. Lodge
  • Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis


    Patent number: 8409566

    Abstract: The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicant's surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.

    Type: Grant

    Filed: February 6, 2009

    Date of Patent: April 2, 2013

    Assignee: Northwest Biotherapeutics, Inc.

    Inventors: Alton L. Boynton, Anil Sehgal, Bridgette Murphy
  • Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines


    Patent number: 8389278

    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14? and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN?, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.

    Type: Grant

    Filed: February 27, 2004

    Date of Patent: March 5, 2013

    Assignee: Northwest Biotherapeutics, Inc.

    Inventors: Benjamin Tjoa, Marnix L. Bosch
  • ISOLATION AND/OR PRESERVATION OF DENDRITIC CELLS FOR PROSTATE CANCER IMMUNOTHERAPY


    Publication number: 20130017600

    Abstract: Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic prostate cancer are disclosed. In one embodiment, human dendritic cells, after exposure to a prostate cancer antigen or specific antigenic peptide, are administered to a prostate cancer patient to activate the relevant T cell responses in vivo. In an alternate embodiment, human dendritic cells are exposed to a prostate cancer antigen or specific antigenic peptide in vitro and incubated or cultured with primed or unprimed T cells to activate the relevant T cell responses in vitro. The activated T cells are then administered to a prostate cancer patient. Methods and compositions for human dendritic cells with extended life span and cryopreserved dendritic cells are disclosed.

    Type: Application

    Filed: June 14, 2012

    Publication date: January 17, 2013

    Applicant: NORTHWEST BIOTHERAPEUTICS, INC.

    Inventors: Gerald P. Murphy, Alton L. Boynton, Benjamin A. Tjoa
  • QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS


    Publication number: 20120252034

    Abstract: The present invention provides methods for evaluating the quality of a preparation of antigen presenting cells, such as dendritic cells.

    Type: Application

    Filed: June 14, 2012

    Publication date: October 4, 2012

    Applicant: NORTHWEST BIOTHERAPEUTICS, INC.

    Inventors: Gopi Shankar, Patricia Anne Lodge, Alan Norman Brunelle
  • ADMINISTRATION OF DENDRITIC CELLS PARTIALLY MATURED IN VITRO FOR THE TREATMENT OF TUMORS


    Publication number: 20120251561

    Abstract: The present invention provides populations of cells comprising partially matured dendritic cells that can be used for administration individuals having a tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 1 to about 10 hours, or more, efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual. Once in the lymph node the now fully mature antigen presenting dendritic cells secrete the appropriate cytokines (e.g., TNF? and IL-12) and contact T cells inducing a substantial anti-tumor immune response.

    Type: Application

    Filed: June 4, 2012

    Publication date: October 4, 2012

    Applicant: NORTHWEST BIOTHERAPEUTICS, INC.

    Inventor: Marnix L. Bosch
  • COMPOSITIONS AND METHODS FOR INDUCING THE ACTIVATION OF IMMATURE MONOCYTIC DENDRITIC CELLS


    Publication number: 20120244620

    Abstract: The present invention provides methods for inducing the maturation of immature dendritic cells (DC) and for activating those cells without the use of a dendritic cell maturation agent. The activated DC can be used for inducing an antigen specific T cell response. Methods of the invention can also comprise the addition of a directional maturation agent, such as interferon gamma, to induce a Th-1 and/or Th-2 bias in the response obtained. The present invention also provides dendritic cell populations useful for activating and for inducing antigen specific T cells. Similarly, activated antigen specific T cell populations, and methods of making the same are provided.

    Type: Application

    Filed: June 8, 2012

    Publication date: September 27, 2012

    Applicant: NORTHWEST BIOTHERAPEUTICS, INC.

    Inventors: Alton L. Boynton, Marnix L. Bosch
  • TANGENTIAL FLOW FILTRATION DEVICES AND METHODS FOR LEUKOCYTE ENRICHMENT


    Publication number: 20110189150

    Abstract: The present invention provides tangential flow filtration devices and methods for enriching a heterogenous mixture of blood constituents for leukocytes by removal of non-leukocyte blood constituents. In one particular embodiment the device can provide a composition enriched in monocytes.

    Type: Application

    Filed: April 13, 2010

    Publication date: August 4, 2011

    Applicant: Northwest Biotherapeutics, Inc.

    Inventors: Marnix L. Bosch, Paul C. Harris, Steven J. Monahan, Allen Turner, Alton L. Boynton, Patricia A. Lodge



  • Tangential flow filtration devices and methods for stem cell enrichment


    Patent number: 7790039

    Abstract: The present invention provides methods for enriching a heterogenous mixture of bone marrow or blood constituents for stem cells by removal of non-stem cell constituents comprising separation of the non-stem cell constituents using a tangential flow filtration device.

    Type: Grant

    Filed: November 18, 2004

    Date of Patent: September 7, 2010

    Assignee: Northwest Biotherapeutics, Inc.

    Inventors: Marnix L. Bosch, Patricia A. Lodge, Julie Anna McEarchern, Alton L. Boynton, Paul G. Hugenholtz
    • Tangential flow filtration devices and methods for leukocyte enrichment


      Patent number: 7695627

      Abstract: The present invention provides tangential flow filtration devices and methods for enriching a heterogeneous mixture of blood constituents for leukocytes by removal of non-leukocyte blood constituents. In one particular embodiment the device can provide a composition enriched in monocytes. One embodiment includes a remover unit (1) having a crossflow chamber (3) separated by a microporous filter (5) from a filtrate chamber (4), the remover unit (1) also having a tangential flow inlet (6), a fluid outlet (7) for a fluid enriched in leukocytes and a filtrate outlet (8).

      Type: Grant

      Filed: June 19, 2003

      Date of Patent: April 13, 2010

      Assignee: Northwest Biotherapeutics, Inc.

      Inventors: Marnix L. Bosch, Paul C. Harris, Steven J. Monahan, Allen Turner, Alton L. Boynton, Patricia A. Lodge
    • THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS


      Publication number: 20100062003

      Abstract: The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicant's surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.

      Type: Application

      Filed: February 6, 2009

      Publication date: March 11, 2010

      Applicant: NORTHWEST BIOTHERAPEUTICS, INC.

      Inventors: GERALD P. MURPHY, ALTON L. BOYNTON, ANIL SEHGAL, BRIDGET MURPHY
    • QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS


      Publication number: 20100008892

      Abstract: The present invention provides methods for evaluating the quality of a preparation of antigen presenting cells, such as dendritic cells. Assays for antigen-independent co-stimulation of T cells and for presentation of predetermined antigen by APCs are provided.

      Type: Application

      Filed: February 4, 2009

      Publication date: January 14, 2010

      Applicant: Northwest Biotherapeutics, Inc.

      Inventors: Gopi Shankar, Patricia Anne Lodge, Alan Norman Brunelle
    • COMPOSITIONS AND METHODS FOR PRIMING MONOCYTIC DENDRITIC CELLS AND T CELLS FOR TH-1 RESPONSE


      Publication number: 20080254064

      Abstract: The present invention provides compositions and methods for inducing maturation of immature dendritic cells (DC) and for priming those cells for inducing a type 1 immune response. The present invention also provides dendritic cell populations useful for activating and for preparing T cells polarized towards production of type 1 cytokines and/or a type 1 response. Similarly, activated, polarized T cell populations, and methods of making the same are provided.

      Type: Application

      Filed: May 29, 2008

      Publication date: October 16, 2008

      Applicant: NORTHWEST BIOTHERAPEUTICS, INC.

      Inventor: Marnix L. Bosch
    • Compositions and Methods for Inducing the Activation of Immature Monocytic Dendritic Cells


      Publication number: 20080254537

      Abstract: The present invention provides methods for inducing the maturation of immature dendritic cells (DC) and for activating those cells without the use of a dendritic cell maturation agent. The activated DC can be used for inducing an antigen specific T cell response. Methods of the invention can also comprise the addition of a directional maturation agent, such as interferon gamma, to induce a Th-I and/or Th-2 bias in the response obtained. The present invention also provides dendritic cell populations useful for activating and for inducing antigen specific T cells. Similarly, activated antigen specific T cell populations, and methods of making the same are provided.

      Type: Application

      Filed: December 8, 2006

      Publication date: October 16, 2008

      Applicant: Northwest Biotherapeutics, Inc.

      Inventors: Alton L. Boynton, Marnix L. Bosch
    • METHOD TO INCREASE CLASS I PRESENTATION OF EXOGENOUS ANTIGENS BY HUMAN DENDRITIC CELLS


      Publication number: 20080171023

      Abstract: Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic cancer are disclosed. In one embodiment, human dendritic cells exposed to a tumor associated antigen, or an antigenic fragment thereof in combination with bacillus Calmette-Guerin (BCG), are administered to a cancer patient to activate a predominantly CD8+T cell response in vivo. In an alternate embodiment, human dendritic cells are exposed to a tumor associated antigen or a specific antigenic peptide in combination with BCG in vitro and incubated or cultured with primed or unprimed T cells to activate a predominantly CD8+T cell response in vitro. The activated T cells are then administered to a cancer patient. Antigen in combination with BCG is processed by dendritic cells through the MHC-CLASS I compartment which provides for a predominantly CD8+T cell response.

      Type: Application

      Filed: January 10, 2008

      Publication date: July 17, 2008

      Applicant: NORTHWEST BIOTHERAPEUTICS, INC.

      Inventors: Michael Salgaller, Alton Boynton
    • Quality assays for antigen presenting cells


      Publication number: 20060234309

      Abstract: The present invention provides methods for evaluating the quality of a preparation of antigen presenting cells, such as dendritic cells. Assays for antigen-independent co-stimulation of T cells and for presentation of predetermined antigen by APC's are provided.

      Type: Application

      Filed: May 8, 2003

      Publication date: October 19, 2006

      Applicant: Northwest Biotherapeutics, Inc

      Inventors: Gopi Shankar, Patricia Lodge, Alan Brunelle
    • HUMAN PARIS-1 ANTIGEN AND NUCLEIC ACIDS: DIAGNOSTIC AND THERAPEUTIC USES


      Publication number: 20060234286

      Abstract: The present invention relates to the discovery, identification and characterization of a novel tumor suppressor gene designated PARIS-1. The invention includes nucleotide sequences of the PARIS-1 gene and amino acid sequences of its encoded protein product(s), as well as fragments, derivatives and analogs thereof. The invention also includes the production of PARIS-1 proteins, fragments and derivatives and of antibodies specific for PARIS-1 gene products. The invention further comprises agents and compositions which can modulate the expression of PARIS-1 or PARIS-1 expression products to effect the proliferation of cells which express PARIS-1. One particular embodiment comprises agents and compounds which can slow or ablate the proliferation of prostate tumor cells.

      Type: Application

      Filed: May 22, 2006

      Publication date: October 19, 2006

      Applicant: Northwest Biotherapeutics, Inc.

      Inventor: Yaling Zhou
    • Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses


      Patent number: 7087715

      Abstract: The present invention relates to the discovery, identification and characterization of a novel tumor suppressor gene designated PARIS-1. The invention includes nucleotide sequences of the PARIS-1 gene and amino acid sequences of its encoded protein product(s), as well as fragments, derivatives and analogs thereof. The invention also includes the production of PARIS-1 proteins, fragments and derivatives and of antibodies specific for PARIS-1 gene products. The invention further comprises agents and compositions which can modulate the expression of PARIS-1 or PARIS-1 expression products to effect the proliferation of cells which express PARIS-1. One particular embodiment comprises agents and compounds which can slow or ablate the proliferation of prostate tumor cells.

      Type: Grant

      Filed: March 13, 2001

      Date of Patent: August 8, 2006

      Assignee: Northwest Biotherapeutics, Inc.

      Inventor: Yaling Zhou
    • Administration of dendritic cells partially matured in vitro for the treatment of tumors


      Publication number: 20060057120

      Abstract: The present invention provides populations of cells comprising partially matured dendritic cells that can be used for administration individuals having a tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 1 to about 10 hours, or more, efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual. Once in the lymph node the now fully mature antigen presenting dendritic cells secrete the appropriate cytokines (e.g., TNF? and IL-12) and contact T cells inducing a substantial anti-tumor immune response.

      Type: Application

      Filed: December 5, 2003

      Publication date: March 16, 2006

      Applicant: Northwest Biotherapeutics Inc.

      Inventor: Marnix Bosch
    • Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis


      Publication number: 20050202019

      Abstract: The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicants' surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.

      Type: Application

      Filed: November 9, 2004

      Publication date: September 15, 2005

      Applicant: Northwest Biotherapeutics, Inc.

      Inventors: Gerald Murphy, Alton Boynton, Anil Sehgal, Bridgette Murphy
    • Tangential flow filtration devices and methods for stem cell enrichment


      Publication number: 20050189297

      Abstract: The present invention provides methods for enriching a heterogenous mixture of bone marrow or blood constituents for stem cells by removal of non-stem cell constituents comprising separation of the non-stem cell constituents using a tangential flow filtration device.

      Type: Application

      Filed: November 18, 2004

      Publication date: September 1, 2005

      Applicant: Northwest Biotherapeutics, Inc.

      Inventors: Marnix Bosch, Patricia Lodge, Julie McEarchern, Alton Boynton, Paul Hugenholtz
    • Nucleic acids and proteins of a rat ganglioside GM1-specific ?1-2fucosyltransferase and uses thereof


      Patent number: 6936448

      Abstract: A rat ganglioside GM1-specific ?1?2fucosyltransferase is disclosed. Nucleotide sequences of a rat ganglioside GM1-specific ?1?2fucosyltransferase, amino acid sequences of its encoded protein (including peptide or polypeptide), and derivatives thereof are described. Also described are fragments (and derivatives and analogs thereof) which comprise a domain of rat ganglioside GM1-specific ?1?2fucosyltransferase with catalytic activity. Methods of production of rat ganglioside GM1-specific ?1?2fucosyltransferase and derivatives and analogs thereof (e.g. by recombinant means) are provided. Methods of inhibiting the function of rat ganglioside GM1-specific ?1?2fucosyltransferase (e.g. by means of antisense RNA) are provided. Methods of commercial scale use of the rat ganglioside GM1-specific ?1?2fucosyltransferase in the production of fucosyl-saccharide compositions are described. Applications of these compositions, e.g. as additives for human nutritive compositions or immunotherapeutics for cancer, are disclosed.

      Type: Grant

      Filed: November 1, 2001

      Date of Patent: August 30, 2005

      Assignee: Northwest Biotherapeutics, Inc.

      Inventors: Eric H. Holmes, Anne L. Sherwood
    • Tangential flow filtration devices and methods for leukocyte enrichment


      Publication number: 20050173315

      Abstract: The present invention provides tangential flow filtration devices and methods for enriching a heterogeneous mixture of blood constituents for leukocytes by removal of non-leukocyte blood constituents. In one particular embodiment the device can provide a composition enriched in monocytes. One embodiment includes a remover unit (1) having a crossflow chamber (3) separated by a microporous filter (5) from a filtrate chamber (4), the remover unit (1) also having a tangential flow inlet (6), a fluid outlet (7) for a fluid enriched in leukocytes and a filtrate outlet (8).

      Type: Application

      Filed: June 19, 2003

      Publication date: August 11, 2005

      Applicant: Northwest Biotherapeutics, Inc.

      Inventors: Marnix Bosch, Paul Harris, Steven Monahan, Allen Turner, Alton Boynton, Patricia Lodge
    • Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis


      Patent number: 6863887

      Abstract: The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicants' surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.

      Type: Grant

      Filed: March 29, 1999

      Date of Patent: March 8, 2005

      Assignee: Northwest Biotherapeutics, Inc.

      Inventors: Bridgette Murphy, Alton L. Boynton, Anil Sehgal, Gerald P. Murphy
    • Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines


      Publication number: 20040203143

      Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14− and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN&ggr;, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.

      Type: Application

      Filed: February 27, 2004

      Publication date: October 14, 2004

      Applicant: Northwest Biotherapeutics, Inc.

      Inventors: Benjamin Tjoa, Marnix L. Bosch
    • Method for induction of proliferation of natural killer cells by dendritic cells cultured with GM-CSF and IL-15


      Publication number: 20040197903

      Abstract: The present invention provides a dendritic cell that can induce the proliferation and activation of natural killer cells. The dendritic cells, designated NK dendritic cells, are characterized by the expression of increased levels of CD80, CD1a, and CD86 as compared to a mature dendritic cell cultured in the presence of granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin 4 (IL-4). Further, the dendritic cells are characterized by the expression of interleukin 12 (IL-12), tumor necrosis factor &agr; (TNF&agr;), and GM-CSF. The NK dendritic cells are produced by providing a cell population comprising low-adherence monocytic dendritic precursor cells that have been cultured in the presence of granulocyte-monocyte colony stimulating factor (GM-CSF) and interleukin 15 (IL-15) and by contacting the cells with an effective amount of a dendritic cell maturation agent.

      Type: Application

      Filed: February 2, 2004

      Publication date: October 7, 2004

      Applicant: Northwest Biotherapeutics, Inc.

      Inventor: Linda Pestano
    • Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen


      Publication number: 20040024188

      Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In. particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM′) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM′ allows the use of an immunoenzymatic assay for their detection.

      Type: Application

      Filed: May 1, 2003

      Publication date: February 5, 2004

      Applicant: Northwest Biotherapeutics, Inc.

      Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William Thomas Tino
    • Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen


      Patent number: 6150508

      Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM') of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM' allows the use of an immunoenzymatic assay for their detection.

      Type: Grant

      Filed: March 18, 1998

      Date of Patent: November 21, 2000

      Assignee: Northwest Biotherapeutics, Inc.

      Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William Thomas Tino
 
最后编辑:
The short are piling on NWBO again as expected as something good will happen after two months gone by without any news. See today's article: Northwest Bio: Biopharma's Promising Delinquent (OTCMKTS:NWBO)

Though the article reflects some investors' anxiety, it is wrong on a lot of things, not well written.

The price now is very attractive, particularly for those who want to initiate a position.

1666118356992.png
 

"
Ellie said after speaking to their oncologist and carrying out their own research there is hope of an effective treatment for Owain. She added: "Immunotherapy (DCVax), which is changing the face of cancer care, is a viable option for Owain. But it comes at a very high cost.


"Essentially a biopsy sample is taken and a vaccine is produced for Owain specifically to fit his unique tumour. Then his body takes over and fights the cancer itself. But the cost of manufacturing the vaccine is £200,000 with additional medical expenses on top.
"
1666121639582.png
 
The same story above but reported also by BBC:

"DCVax, a type of immunotherapy, uses a vaccine which utilises the body's immune cells to target the cancer.
It is currently in the third phase of clinical trials but initial results suggest it could help patients like Owain."

and "Optune [nvcr with market cap of roughly 10 billion] is a device that looks like a skull cap which creates electrical fields to disrupt tumour cell division.
In 2018, the body which advises the NHS on treatments, NICE, said there was "insufficient evidence of its clinical effectiveness in terms of improvement in overall survival and progression-free survival to make the technology cost effective".

 

Can NWBO get me through this torturous yet also opportunistic time? All signs point to being positive despite depressed price. But now can the timing also be opportunistic?​

Where Are Markets Headed? Six Pros Take Their Best Guess​

Heavyweights in the world of finance, from Jeremy Grantham to Lloyd Blankfein, describe their view of the future amid lots of uncertainty. They agree the wild ride isn’t over yet​

1667065696102.png
1667065734999.png
1667065766055.png
1667065794186.png
1667065821875.png


A massive selloff in bonds. A plunge in tech stocks. The implosion of cryptocurrencies. The highest inflation in four decades.

Amid a brutal and uncertain climate, we asked six heavyweights in the world of finance to share their thoughts on the state of the markets, how they have handled this year’s carnage and what they anticipate in the future.

The market watchers disagreed on some fundamental issues. Jeremy Grantham, best known for predicting the market crashes of 2000 and 2008, gave many reasons to be pessimistic even after the initial bursting of what he called “a super bubble.” Investing pioneer Rob Arnott, the founder of Research Affiliates, agrees the market hasn’t yet hit bottom. Lloyd Blankfein, the former chief executive of Wall Street giant Goldman Sachs Group Inc., GS 1.38%increase; green up pointing triangle
says things aren’t as bad as they seem.

Most do agree this wild ride isn’t going to smooth out anytime soon.

Wait for peak fear​

Investors should wait until markets have hit their bottom to buy, says Mr. Arnott. And that hasn’t happened yet, in his opinion.

Buy too early, and your investments will fall further. Buy too late, and you will have missed the best opportunity to make a profit.

U.S. stocks still look expensive to Mr. Arnott, the son of a pastor who turned a love of computers, math and research into investment advisory business Research Affiliates. He is known within his industry as the “godfather of smart beta,” a reference to funds that allocate money based on factors like companies’ dividend payments, sales, or volatility.


2006'10'15'2010152025303540

The problem is, identifying the moment of peak fear—when investors have gotten so pessimistic there’s nowhere for prices to go but up—almost always boils down to guesswork, Mr. Arnott said.

He is convinced U.S. stocks haven’t hit their trough. Why? The Shiller price-to-earnings ratio—a measure of the market’s overall valuation named after Nobel Prize-winning Yale economist Robert Shiller—shows that equities are still relatively pricey. The S&P 500 is trading well below its peaks during the dot-com bust and post-pandemic rally but far above the range reached during the worst of the 2007-09 financial crisis. That doesn’t seem to suggest that investors have reached the point of capitulation.

“I’ve been called a permabear,” he said. “But I’m a bear on things that are expensive. I don’t want to bother buying them, even if they could go higher.”

Akane Otani

Things aren’t as bad as they seem​

Mr. Blankfein, who steered Goldman Sachs through the brutal 2008-09 financial crisis, said the market’s outlook may not be as dire as many believe.

Share Your Thoughts​

How are you navigating the markets right now? Join the conversation below.
“The bad news is so stacked up that people are under-appreciating the fact that there are several plausible pieces of good news that could affect the market positively,” he said, citing a change in Russia’s approach to the war in Ukraine, the release of more oil by Saudi Arabia and a pause in rate hikes by the Fed. “Markets are not just the current economy, they look ahead.”

This year’s selloff has been equally punishing for many stocks, he said. “Move into those you wished you owned but were too expensive.”

Mr. Blankfein said it’s worth remembering the challenges of the moment always seem worse than those of the past, if only because the past is resolved. And history, like the markets, has cycles.

The Intelligent Investor​


“You think things have never been scarier?” said Mr. Blankfein, who retired from Goldman in 2018. “Really? We lived through the Cuban missile crisis when we were stopping Soviet ships in international waters. These are really the most polarized times? I was around in 1968 when there were assassinations of public figures, when kids were blowing up draft centers, and the National Guard was shooting on campuses. We got through that, we’ll get through this.

“It’s never as bad as your worst fears or as good as your best hopes,” he added.

Justin Baer

Prepare for more chaos​

Volatility is here to stay. That’s the view of Paul Britton, founder of investment firm Capstone Investment Advisors and someone who bets on haywire swings across global markets.

He expects rising interest rates to keep stoking turmoil, with few corners of the markets sheltered from the pain. Even bonds, typically thought of as a safer investment than stocks, have grown more volatile.

That makes many investors’ portfolios riskier than they appear, Mr. Britton says. The yield on the 10-year Treasury note, typically thought of as ultrasafe, has recorded some of its largest one-day moves of the past decade in recent months.
This turbulence, he said, means investors need to rethink what will buffer their portfolios and consider holdings beyond stocks and bonds. “The strategies that have worked best the past 15 years are not necessarily the strategies that are going to perform the next 15 years,” Mr. Britton said. “There is a structural shift that we haven’t seen in decades.”

At his firm, which oversees roughly $8.9 billion in assets and manages money for pension funds and endowments, Mr. Britton says he is particularly optimistic about a so-called dispersion strategy designed to profit from volatility. The complex tactic uses options to wager on how tightly stocks will rise and fall together.

“This is one of those moments in time where I think it’s crucial to be brave in your decision making,” Mr. Britton said.

Gunjan Banerji

Inflation isn’t going away​

Investors are clinging to the belief that inflation will dissipate soon, says Nancy Davis, founder of asset management firm Quadratic Capital Management LLC, which oversees roughly $1.2 billion. They shouldn’t, in her view.

Inflation reached a four-decade high this year as the price of everything from groceries to gas soared. Federal Reserve Chairman Jerome Powell has made it clear he doesn’t expect that situation to change. He even abandoned the use of “transitory” when discussing the subject, saying roughly 11 months ago that ”it’s probably a good time to retire that word.”

“The Fed retired it, but the market is still pricing for transitory,” said Ms. Davis, who warned about the dangers of inflation in early 2021. “That to me is where there’s an opportunity.”
She cited the fact that inflation expectations among investors have been falling this year, even as data on consumer prices has shown continued gains. A widely-followed measure of investors’ annual inflation expectations over the next half-decade—the five-year breakeven inflation rate—stood recently at around 2.6%, according to Tradeweb. Year-over-year inflation is currently more than 8%, far above the Fed’s 2% target. This means investors expect inflation to tumble over the next five years, she said, and that bond-market investors may be too confident the Fed’s rate hikes will eventually bring inflation down.

She is preparing by holding mostly inflation-protected bonds and options tied to interest rates in the $1.1 billion Quadratic Interest Rate Volatility and Inflation Hedge Exchange-Traded Fund, where she is portfolio manager. These positions would serve as a hedge if inflation doesn’t subside, she said.

—Gunjan Banerji

The ‘super bubble’ is still bursting​

Mr. Grantham is legendary for spotting bubbles before markets crash. He did so in the lead-up to the tech-stock implosion of 2000, and before the financial crisis that began in 2008.

The co-founder of investment firm Grantham Mayo Van Otterloo & Co. gained renewed attention this year when he said U.S. markets were experiencing a “super bubble” in the very early stages of an ugly deflation. Nine months after that statement, Mr. Grantham remains deeply pessimistic.

“This is about as bad a package [of fundamentals] as we have ever seen,” says Mr. Grantham, who is board chairman and long-term investment strategist for his firm, which managed $59 billion as of June 30. Stock valuations, he says, remain well above their long-term averages. This is true even though economic growth has slowed, inflation has returned and interest rates have reversed after a long decline that had helped lift stocks for decades.
Mr. Grantham has put his own money in a family foundation that has allocated about half of its assets to young companies developing green technology, another 25% to other early-stage businesses and the remaining 25% to a few different investments, including one that benefits when the Nasdaq Composite falls in value and another that profits when investors see rising risk of corporate defaults.

For average investors, he says, holding cash is among the best options. He rejects the mantra that you shouldn’t try to time the market, pointing out several examples from history when it took years, or even decades, for markets to recover from crashes.

Sam Goldfarb

Bonds should bounce back​

Bonds have had their worst year on record. That is one reason to be optimistic about next year, according to the man responsible for overseeing roughly $2.3 trillion in assets for the world’s largest money manager.

“I’m more excited going into 2023 than I’ve been in a really long time because we’re going to have so many different opportunities,” says Rick Rieder, BlackRock Inc.’s chief investment officer of global fixed income.

Investors typically value bonds with good credit ratings for their safe returns. Yet the Bloomberg U.S. Aggregate bond index has returned minus 16% this year—its worst-ever performance by far.
The problem: To fight inflation, the Federal Reserve has been raising interest rates at a historic pace and kept promising more ahead. That reduces the value of bonds issued when rates were lower.

Bond investors, Mr. Rieder acknowledges, have been hopeful before, only for more dismal inflation reports to further damage their portfolios. But he now sees clear signs that higher rates are starting to have their intended effect of slowing down the economy. That means that the Fed may not need to raise rates much higher than it is already projecting.

The good news for investors is that lower bond prices mean higher yields, or better forward-looking returns. That is true for old bonds that have dropped below face value and new bonds issued at higher interest rates.

With prices unlikely to keep falling like they have been, “you can feel pretty good about buying literally triple-A assets at these sort of yields,” Mr. Rieder says.

Sam Goldfarb
 
Something positive would definitely happen in Nov, which starts tomorrow.
1667224809383.png
 
后退
顶部